The patent application is for a novel taste-masking formulation which CyDex has developed. CyDex’s Captisol has been combined with Sertraline. Key benefits of this formulation by CyDex are: the previously bitter taste of the drug is masked; no dilution of the medicine is required; and, as an oral concentrate, this formulation may be administered via multiple beverages such as juice, soda, etc without precipitation.
The second medical patent to be auctioned is one for a formulation containing Propofol and Captisol. Propofol is a sedative hypnotic drug, and in this patented formulation, there is reduced incidence of pain upon injection.
Propofol is most commonly used as a short-acting intravenous sedative agent before the introduction of general anesthesia and during maintenance of general anesthesia.
Ralph Johnston, vice president of business development and marketing at CyDex, said: “CyDex Pharmaceuticals is selling the patent application for the Sertraline formulation and the patent for the Propofol formulation because these two developments are outside of the corporation’s target markets.”